Infectious Diseases

At IDWeek 2023, a presentation on the challenges to the diagnosis and management of VAIs in children.

At IDWeek 2023, updates on CLABSIs in the pediatric population.

At IDWeek 2023, a presenter shares his own studies on the impact of viral effects after infection.

At IDWeek 2023, a presenter discusses the future of infection prevention from organ transplants in children.

At IDWeek 2023, several authors share a study on mother-infant pairs, evaluating for differences in rates of influenza infections in infants.

At IDWeek 2023, a discussion of the best end of therapy for Gram-negative neonatal meningitis.

At IDWeek 2023, a session on TB, which remains a formidable foe in global pediatric health.

At IDWeek 2023, a presentation on the emotional and financial cost of climate change, and what clinicians can do right now to help.

At ID Week 2023, 2 health care providers argue the pros and cons of treatments for newborns with bacteremic UTIs.

At IDWeek 2023, a White House expert on Mpox discusses initial reactions to the outbreak, vaccination rates, and where we need to do better in combatting this infectious disease.

At IDWeek 2023, a presentation on the latest recommendations for screening and management of hepatitis C in the pediatric population.

At a plenary session at IDWeek 2023, the benefits and challenges of using AI in treating infectious diseases was discussed.

New immunizations for RSV are making this respiratory infection preventable in ways it never was before. Here is the latest news on recent approvals and future outlooks.

A look at recent approvals and promising clinical trials for future vaccines.

As we head into cold and flu season, researchers try to answer the question of what physical interventions are best for infection prevention.

A refresher on best interventions for common respiratory disorders in children.

Due to increased RSV activity observed in Southeastern regions of the United States, the Centers for Disease Control and Prevention (CDC) has issued an official Health Alert Network Health Advisory. The CDC recommends that clinicians prepare to implement recently FDA-approved prevention methods.

Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses what Pfizer's recently FDA-approved RSV vaccine means for infants ahead of the traditional RSV season.

Approved for use at 32 weeks through 36 weeks gestation, Pfizer’s maternal respiratory syncytial vaccine (Abrysvo), is delivered through a single dose injection to the muscle, and is the first vaccine for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD because of RSV in infants (birth to 6 months).

Basis for a Biologics License Application submission to the FDA is being built for PXVX0317, following topline results demonstrated in a pair of phase 3 trials, including 1 trial featuring adolescents and adults aged 12 to 64 years.

As children get ready to return to school, pediatric health care providers may start seeing more of this condition in their offices. Here is what you should know.

Previously available under an Emergency Use Authorization, the combination test can detect and distinguish COVID-19, influenza A/B, and respiratory syncytial virus (RSV). The clearance comes ahead of respiratory season, which, according to BD, could result in another “tripledemic” threat.

Ervebo has been approved by the FDA to prevent the Ebola virus for individuals aged 12 months and older, after being initially approved for those 18 years and older in 2019.

Prevention and treatment strategies for tick-borne diseases and respiratory infections

Expanding peripartum prophylaxis could be more cost-effective, but would likely lead to significant over-treatment.